BeNeLuxBelgiumNetherlandsLuxembourg

Prosensa and GlaxoSmithKline expand Duchenne dystrophy alliance

24.06.2010

Leiden - Prosensa NV and British drugmaker GlaxoSmithKline have expanded their cooperation concerning RNA-modulating drugs against Duchenne muscular dystrophy (DMD). Two programmes, covering 4 drug new drug candidates for specific patient subpopulations, have been added to the existing collaboration in DMD. According to the terms of the agreement, GSK has paid two upfront fees and will add milestones dependant on research progress. Within the new programmes, Prosensa and GSK will focus on the skipping of four exons (exon 45, 52, 53, and 55), in addition to their existing programmes that target skipping of exon 51 and 44 (PRO051/GSK2402968 and PRO044). GSK has an option to select two of these additional four compounds for later-stage development and commercialization. Prosensa will retain certain limited European commercialisation rights alongside GSK for the two compounds selected by GSK. For the two compounds not selected by GSK, Prosensa will retain full commercialization rights.

BeNeLuxBelgiumNetherlandsLuxembourg

14.08.2008

Gent – Belgian Innogenetics NV is the object of a bidding war. After chemical company Solvay tendered its offer to acquire 93% of the diagnostics specialist in April, San-Diego-based Gen-Probe also entered the arena, offering to...

BeNeLuxBelgiumNetherlandsLuxembourg

14.08.2008

Belgian Ablynx N.V. (Ghent) has started a Phase Ib safety and dose-finding study of ALX-0081, an antithrombotic antibody fragment that targets von Willebrand factor (vWF).

BeNeLuxBelgiumNetherlandsLuxembourg

14.08.2008

Amsterdam Molecular Therapeutics finished enrolment in its Phase III trial in mid-June in its AAAV-based gene therapy AMT-011 (Glybera®) programme for the correction of lipoprotein lipase deficiency. The company had previously...

BeNeLuxBelgiumNetherlandsLuxembourg

20.05.2008

Brussels – Unprocessed grains of Syngenta’s herbicide-tolerant biotech maize GA21 have been approved for use in the European Union for an initial period of 10 years, according to a European Commission decision. The genetically...

BeNeLuxBelgiumNetherlandsLuxembourg

20.05.2008

Brussels – To ensure that new genetic tests become available to patients, European human geneticists have called for a ban on patents covering disease genes and related SNPs. Additionally, the group under Prof. Gert Matthijs...

BeNeLuxBelgiumNetherlandsLuxembourg

20.05.2008

The Hague – The District Court of The Hague in the Netherlands has ruled that the basic patent covering atorvastatin – the active ingredient of Pfizer’s bestseller Lipitor – would be infringed by a competitor product from Indian...

BeNeLuxBelgiumNetherlandsLuxembourg

20.05.2008

Maastricht – The Netherlands, Belgian and German regions will cooperate closer in the development of the life sciences after representatives signed a letter of intent at the 2nd Biomedica conference in Maastricht. Dutch ministers...

BeNeLuxBelgiumNetherlandsLuxembourg

20.05.2008

Amsterdam – The Netherlands will become the seventeenth country in Western Europe to recommend HPV vaccination for adolescent girls. The Dutch Health Council has recommended to the ministry that the vaccine be given to to...

BioPeople, BeNeLuxBelgiumNetherlandsLuxembourg

26.03.2008

UCB has appointed Fabrice Enderlin, the company’s Executive Vice President of Corporate Human Resources, as a new member of UCB’s Executive Committee. Enderlin will be taking over the position from Jean-Pierre Pradier, who will...

BeNeLuxBelgiumNetherlandsLuxembourg

19.03.2008

Mechelen – Belgian drug discovery company Galapagos NV has withdrawn its listing on London’s Alternative Investment Market AIM. Instead, the board of directors has decided to launch a “Level 1 American Depositary Receipt (ADR)”...

Displaying results 161 to 170 out of 304

< Previous 161-170 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/16/article/prosensa-and-glaxosmithkline-expand-duchenne-dystrophy-alliance.html

Stock list

All quotes

TOP

  • MAGFORCE (D)5.90 EUR9.26%
  • ABCAM (UK)387.00 GBP7.72%
  • NANOBIOTIX (F)17.40 EUR7.27%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.40 EUR-8.33%

TOP

  • WILEX (D)3.12 EUR300.0%
  • SANTHERA (CH)69.30 CHF103.8%
  • ADDEX (CH)4.07 CHF82.5%

FLOP

  • MERCK KGAA (D)63.71 EUR-50.0%
  • HYBRIGENICS (F)1.72 EUR-34.4%
  • PROSENSA (NL)9.24 USD-24.4%

TOP

  • SANTHERA (CH)69.30 CHF3453.8%
  • GW PHARMACEUTICALS (UK)438.00 GBP800.9%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.25 CHF-92.6%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)8.87 EUR-71.8%

No liability assumed, Date: 23.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events